CTOs on the Move

CalciMedica

www.calcimedica.com

 
CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

CalciMedica raised $15M on 05/22/2020
CalciMedica raised $21M on 03/11/2021

Similar Companies

Human Longevity

Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world`s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.

Prodesse

Prodesse is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mobilion Systems

MOBILion Systems is enabling advancements in disease diagnosis and treatment by commercializing instruments that improve multi-omics disease, drug, and biomarker discovery.

Cerulean

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of NDCs designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. Our first platform-generated candidate, CRLX101, is in multiple clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated candidate, CRLX301, is in a Phase 1/2a clinical trial.

Octave Bioscience

Octave is developing a comprehensive, first-in-class Care Management Platform.